CVRx is a commercial-stage medical device company. Co.'s proprietary platform technology, Barostim, is designed to utilize the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure (HF) and other cardiovascular diseases. Co.'s product, Barostim, is commercially available neuromodulation device indicated to improve symptoms for patients with HF with reduced Ejection Fraction. Barostim provides Baroreflex Activation Therapy by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate the cardiovascular function. The CVRX average annual return since 2021 is shown above.
The Average Annual Return on the CVRX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CVRX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CVRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|